PharmaShots | Incisive News in 3 Shots

Subscribe Now

BioXcel Therapeutics

Insights+: The US FDA New Drug Approvals in April 2022

Insights+: The US FDA New Drug Approvals in April 2022

May 19, 2022

BioXcel Therapeutics’ Igalmi (dexmedetomidine) Receives the US FDA’s Approval for Acute Treatment of Agitation Associated with Schizophrenia or Bipolar I or II Disorder

BioXcel Therapeutics’ Igalmi (dexmedetomidine) Receives the US FDA’s Approval for Acute Treatment of Agitation Associated with Sch...

April 7, 2022

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us